J Chem Inf Model - Virtual drug screen schema based on multiview similarity integration and ranking aggregation.

Tópicos

{ compound(1573) activ(1297) structur(1058) }
{ perform(1367) use(1326) method(1137) }
{ data(3008) multipl(1320) sourc(1022) }
{ method(1219) similar(1157) match(930) }
{ gene(2352) biolog(1181) express(1162) }
{ import(1318) role(1303) understand(862) }
{ analysi(2126) use(1163) compon(1037) }
{ can(774) often(719) complex(702) }
{ learn(2355) train(1041) set(1003) }
{ bind(1733) structur(1185) ligand(1036) }
{ perform(999) metric(946) measur(919) }
{ take(945) account(800) differ(722) }
{ concept(1167) ontolog(924) domain(897) }
{ use(976) code(926) identifi(902) }
{ use(1733) differ(960) four(931) }
{ system(1976) rule(880) can(841) }
{ research(1085) discuss(1038) issu(1018) }
{ method(2212) result(1239) propos(1039) }
{ method(1557) propos(1049) approach(1037) }
{ design(1359) user(1324) use(1319) }
{ howev(809) still(633) remain(590) }
{ result(1111) use(1088) new(759) }
{ imag(1947) propos(1133) code(1026) }
{ inform(2794) health(2639) internet(1427) }
{ imag(2675) segment(2577) method(1081) }
{ clinic(1479) use(1117) guidelin(835) }
{ featur(1941) imag(1645) propos(1176) }
{ risk(3053) factor(974) diseas(938) }
{ state(1844) use(1261) util(961) }
{ method(1969) cluster(1462) data(1082) }
{ model(3404) distribut(989) bayesian(671) }
{ data(1737) use(1416) pattern(1282) }
{ measur(2081) correl(1212) valu(896) }
{ imag(1057) registr(996) error(939) }
{ sequenc(1873) structur(1644) protein(1328) }
{ featur(3375) classif(2383) classifi(1994) }
{ imag(2830) propos(1344) filter(1198) }
{ network(2748) neural(1063) input(814) }
{ patient(2315) diseas(1263) diabet(1191) }
{ studi(2440) review(1878) systemat(933) }
{ motion(1329) object(1292) video(1091) }
{ assess(1506) score(1403) qualiti(1306) }
{ treatment(1704) effect(941) patient(846) }
{ surgeri(1148) surgic(1085) robot(1054) }
{ framework(1458) process(801) describ(734) }
{ problem(2511) optim(1539) algorithm(950) }
{ error(1145) method(1030) estim(1020) }
{ chang(1828) time(1643) increas(1301) }
{ algorithm(1844) comput(1787) effici(935) }
{ extract(1171) text(1153) clinic(932) }
{ data(1714) softwar(1251) tool(1186) }
{ control(1307) perform(991) simul(935) }
{ model(2220) cell(1177) simul(1124) }
{ care(1570) inform(1187) nurs(1089) }
{ general(901) number(790) one(736) }
{ method(984) reconstruct(947) comput(926) }
{ search(2224) databas(1162) retriev(909) }
{ case(1353) use(1143) diagnosi(1136) }
{ data(3963) clinic(1234) research(1004) }
{ studi(1410) differ(1259) use(1210) }
{ system(1050) medic(1026) inform(1018) }
{ model(2341) predict(2261) use(1141) }
{ visual(1396) interact(850) tool(830) }
{ studi(1119) effect(1106) posit(819) }
{ blood(1257) pressur(1144) flow(957) }
{ spatial(1525) area(1432) region(1030) }
{ record(1888) medic(1808) patient(1693) }
{ health(3367) inform(1360) care(1135) }
{ model(3480) simul(1196) paramet(876) }
{ monitor(1329) mobil(1314) devic(1160) }
{ ehr(2073) health(1662) electron(1139) }
{ research(1218) medic(880) student(794) }
{ patient(2837) hospit(1953) medic(668) }
{ model(2656) set(1616) predict(1553) }
{ data(2317) use(1299) case(1017) }
{ age(1611) year(1155) adult(843) }
{ medic(1828) order(1363) alert(1069) }
{ signal(2180) analysi(812) frequenc(800) }
{ cost(1906) reduc(1198) effect(832) }
{ group(2977) signific(1463) compar(1072) }
{ sampl(1606) size(1419) use(1276) }
{ first(2504) two(1366) second(1323) }
{ intervent(3218) particip(2042) group(1664) }
{ activ(1138) subject(705) human(624) }
{ time(1939) patient(1703) rate(768) }
{ patient(1821) servic(1111) care(1106) }
{ use(2086) technolog(871) perceiv(783) }
{ can(981) present(881) function(850) }
{ health(1844) social(1437) communiti(874) }
{ structur(1116) can(940) graph(676) }
{ high(1669) rate(1365) level(1280) }
{ cancer(2502) breast(956) screen(824) }
{ drug(1928) target(777) effect(648) }
{ implement(1333) system(1263) develop(1122) }
{ survey(1388) particip(1329) question(1065) }
{ estim(2440) model(1874) function(577) }
{ decis(3086) make(1611) patient(1517) }
{ process(1125) use(805) approach(778) }
{ activ(1452) weight(1219) physic(1104) }
{ detect(2391) sensit(1101) algorithm(908) }

Resumo

The current drug virtual screen (VS) methods mainly include two categories. i.e., ligand/target structure-based virtual screen and that, utilizing protein-ligand interaction fingerprint information based on the large number of complex structures. Since the former one focuses on the one-side information while the later one focuses on the whole complex structure, they are thus complementary and can be boosted by each other. However, a common problem faced here is how to present a comprehensive understanding and evaluation of the various virtual screen results derived from various VS methods. Furthermore, there is still an urgent need for developing an efficient approach to fully integrate various VS methods from a comprehensive multiview perspective. In this study, our virtual screen schema based on multiview similarity integration and ranking aggregation was tested comprehensively with statistical evaluations, providing several novel and useful clues on how to perform drug VS from multiple heterogeneous data sources. (1) 18 complex structures of HIV-1 protease with ligands from the PDB were curated as a test data set and the VS was performed with five different drug representations. Ritonavir ( 1HXW ) was selected as the query in VS and the weighted ranks of the query results were aggregated from multiple views through four similarity integration approaches. (2) Further, one of the ranking aggregation methods was used to integrate the similarity ranks calculated by gene ontology (GO) fingerprint and structural fingerprint on the data set from connectivity map, and two typical HDAC and HSP90 inhibitors were chosen as the queries. The results show that rank aggregation can enhance the result of similarity searching in VS when two or more descriptions are involved and provide a more reasonable similarity rank result. Our study shows that integrated VS based on multiple data fusion can achieve a remarkable better performance compared to that from individual ones and, thus, serves as a promising way for efficient drug screening, taking advantages of the rapidly accumulated molecule representations and heterogeneous data in the pharmacological area.

Resumo Limpo

current drug virtual screen vs method main includ two categori ie ligandtarget structurebas virtual screen util proteinligand interact fingerprint inform base larg number complex structur sinc former one focus onesid inform later one focus whole complex structur thus complementari can boost howev common problem face present comprehens understand evalu various virtual screen result deriv various vs method furthermor still urgent need develop effici approach fulli integr various vs method comprehens multiview perspect studi virtual screen schema base multiview similar integr rank aggreg test comprehens statist evalu provid sever novel use clue perform drug vs multipl heterogen data sourc complex structur hiv proteas ligand pdb curat test data set vs perform five differ drug represent ritonavir hxw select queri vs weight rank queri result aggreg multipl view four similar integr approach one rank aggreg method use integr similar rank calcul gene ontolog go fingerprint structur fingerprint data set connect map two typic hdac hsp inhibitor chosen queri result show rank aggreg can enhanc result similar search vs two descript involv provid reason similar rank result studi show integr vs base multipl data fusion can achiev remark better perform compar individu one thus serv promis way effici drug screen take advantag rapid accumul molecul represent heterogen data pharmacolog area

Resumos Similares

J Chem Inf Model - An integrated virtual screening approach for VEGFR-2 inhibitors. ( 0,731688545810914 )
Brief. Bioinformatics - Similarity-based machine learning methods for predicting drug-target interactions: a brief review. ( 0,688561277264791 )
J Chem Inf Model - Consensus models of activity landscapes with multiple chemical, conformer, and property representations. ( 0,683264171500004 )
J Chem Inf Model - Neighborhood-based prediction of novel active compounds from SAR matrices. ( 0,676925910645225 )
J Chem Inf Model - Using information from historical high-throughput screens to predict active compounds. ( 0,668741859379437 )
J Chem Inf Model - Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures. ( 0,667285567823807 )
J Chem Inf Model - Evaluation and optimization of virtual screening workflows with DEKOIS 2.0--a public library of challenging docking benchmark sets. ( 0,659611982502274 )
J Chem Inf Model - Bioturbo similarity searching: combining chemical and biological similarity to discover structurally diverse bioactive molecules. ( 0,654551580365335 )
J Chem Inf Model - Structure-based fragment hopping for lead optimization using predocked fragment database. ( 0,654295502352273 )
J Chem Inf Model - Heterogeneous classifier fusion for ligand-based virtual screening: or, how decision making by committee can be a good thing. ( 0,650229574097356 )
J Chem Inf Model - Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors. ( 0,648778555453716 )
J Chem Inf Model - Plane of best fit: a novel method to characterize the three-dimensionality of molecules. ( 0,637115930172585 )
J Chem Inf Model - Virtual screening data fusion using both structure- and ligand-based methods. ( 0,635658141834123 )
J Chem Inf Model - ALiBERO: evolving a team of complementary pocket conformations rather than a single leader. ( 0,634983638977572 )
J Chem Inf Model - Ligand-based target prediction with signature fingerprints. ( 0,630592631202823 )
Brief. Bioinformatics - Mining small-molecule screens to repurpose drugs. ( 0,629604201081033 )
J Chem Inf Model - Computer-aided structure-based design of multitarget leads for Alzheimer's disease. ( 0,626196477453547 )
J Chem Inf Model - Dual histamine H3R/serotonin 5-HT4R ligands with antiamnesic properties: pharmacophore-based virtual screening and polypharmacology. ( 0,625135762988212 )
J Chem Inf Model - AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. ( 0,62405460556301 )
J Chem Inf Model - Use of experimental design to optimize docking performance: the case of LiGenDock, the docking module of LiGen, a new de novo design program. ( 0,620996170444639 )
J Chem Inf Model - Identification of novel serotonin transporter compounds by virtual screening. ( 0,620580548175568 )
J Chem Inf Model - How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. ( 0,619238194664746 )
J Integr Bioinform - Coex-Rank: An approach incorporating co-expression information for combined analysis of microarray data. ( 0,617669007648677 )
J Chem Inf Model - Application of computer-aided drug repurposing in the search of new cruzipain inhibitors: discovery of amiodarone and bromocriptine inhibitory effects. ( 0,61747916969156 )
J Chem Inf Model - BioSM: metabolomics tool for identifying endogenous mammalian biochemical structures in chemical structure space. ( 0,614371452572925 )
J Chem Inf Model - Multitarget structure-activity relationships characterized by activity-difference maps and consensus similarity measure. ( 0,612241596271198 )
J Chem Inf Model - QSAR modeling of imbalanced high-throughput screening data in PubChem. ( 0,608839329945423 )
Brief. Bioinformatics - Network biology methods integrating biological data for translational science. ( 0,608225245984318 )
J Chem Inf Model - Rapid scanning structure-activity relationships in combinatorial data sets: identification of activity switches. ( 0,605328075025478 )
J Chem Inf Model - A multivariate chemical similarity approach to search for drugs of potential environmental concern. ( 0,604826104672568 )
J Chem Inf Model - COSMOsim3D: 3D-similarity and alignment based on COSMO polarization charge densities. ( 0,602853524388199 )
J Chem Inf Model - Dependence of QSAR models on the selection of trial descriptor sets: a demonstration using nanotoxicity endpoints of decorated nanotubes. ( 0,600018431966763 )
J Chem Inf Model - Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor. ( 0,598064515309742 )
J Chem Inf Model - Advances in the replacement and enhanced replacement method in QSAR and QSPR theories. ( 0,594911376844279 )
J Chem Inf Model - Identification of multitarget activity ridges in high-dimensional bioactivity spaces. ( 0,594817826147401 )
J Chem Inf Model - Noncontiguous atom matching structural similarity function. ( 0,594619884089029 )
J Chem Inf Model - Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9. ( 0,593509343852137 )
J Chem Inf Model - Design of multitarget activity landscapes that capture hierarchical activity cliff distributions. ( 0,592889914038695 )
J Chem Inf Model - Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors. ( 0,592408046560725 )
J Chem Inf Model - Improvement of virtual screening results by docking data feature analysis. ( 0,59145549851088 )
J Chem Inf Model - Ligand and decoy sets for docking to G protein-coupled receptors. ( 0,59135772919068 )
J Chem Inf Model - SimG: an alignment based method for evaluating the similarity of small molecules and binding sites. ( 0,589349461040346 )
J Chem Inf Model - Characterizing the diversity and biological relevance of the MLPCN assay manifold and screening set. ( 0,589129093786194 )
J Chem Inf Model - Multiobjective particle swarm optimization: automated identification of structure-activity relationship-informative compounds with favorable physicochemical property distributions. ( 0,586458469256517 )
J Chem Inf Model - Assessing the confidence level of public domain compound activity data and the impact of alternative potency measurements on SAR analysis. ( 0,585954643180653 )
J Chem Inf Model - Exploiting structural information in patent specifications for key compound prediction. ( 0,584681491811385 )
J Chem Inf Model - Improved machine learning models for predicting selective compounds. ( 0,583730124684906 )
J Chem Inf Model - Systematic identification of scaffolds representing compounds active against individual targets and single or multiple target families. ( 0,583152110876056 )
J Chem Inf Model - Chemical name to structure: OPSIN, an open source solution. ( 0,58279525955734 )
J Chem Inf Model - Exploration of 3D activity cliffs on the basis of compound binding modes and comparison of 2D and 3D cliffs. ( 0,582106941999682 )
J Chem Inf Model - Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space. ( 0,580672781647607 )
J Chem Inf Model - Visualization and virtual screening of the chemical universe database GDB-17. ( 0,58059480767471 )
J Chem Inf Model - Boosting virtual screening enrichments with data fusion: coalescing hits from two-dimensional fingerprints, shape, and docking. ( 0,580209236178431 )
J Chem Inf Model - Target-independent prediction of drug synergies using only drug lipophilicity. ( 0,579712748017881 )
J Chem Inf Model - SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening. ( 0,578374448714566 )
J Chem Inf Model - ReverseScreen3D: a structure-based ligand matching method to identify protein targets. ( 0,578367956324154 )
J Chem Inf Model - Identification of novel malarial cysteine protease inhibitors using structure-based virtual screening of a focused cysteine protease inhibitor library. ( 0,578104044324172 )
Methods Inf Med - Supporting regenerative medicine by integrative dimensionality reduction. ( 0,577621970887472 )
J Chem Inf Model - Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. ( 0,576896498809179 )
J Chem Inf Model - Conditional probabilistic analysis for prediction of the activity landscape and relative compound activities. ( 0,576849420582176 )
J Chem Inf Model - Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery. ( 0,575688961517645 )
IEEE Trans Pattern Anal Mach Intell - A Prototype Learning Framework Using EMD: Application to Complex Scenes Analysis. ( 0,573975192313913 )
J Chem Inf Model - SAR monitoring of evolving compound data sets using activity landscapes. ( 0,573808249933467 )
J Chem Inf Model - Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation. ( 0,573531065494349 )
J Chem Inf Model - Navigating high-dimensional activity landscapes: design and application of the ligand-target differentiation map. ( 0,572968966844866 )
J Chem Inf Model - SABRE: ligand/structure-based virtual screening approach using consensus molecular-shape pattern recognition. ( 0,572576870707338 )
J Chem Inf Model - Scanning structure-activity relationships with structure-activity similarity and related maps: from consensus activity cliffs to selectivity switches. ( 0,572126092097292 )
J Chem Inf Model - Structural similarity based kriging for quantitative structure activity and property relationship modeling. ( 0,571253389511054 )
J Chem Inf Model - Single R-Group Polymorphisms (SRPs) and R-cliffs: an intuitive framework for analyzing and visualizing activity cliffs in a single analog series. ( 0,571140432344287 )
J Chem Inf Model - Application of support vector machine to three-dimensional shape-based virtual screening using comprehensive three-dimensional molecular shape overlay with known inhibitors. ( 0,570265284271139 )
Brief. Bioinformatics - Toward more realistic drug-target interaction predictions. ( 0,570134934004146 )
J Chem Inf Model - Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations. ( 0,569655857834517 )
J Chem Inf Model - From activity cliffs to activity ridges: informative data structures for SAR analysis. ( 0,568700689417143 )
J Chem Inf Model - PyDPI: freely available python package for chemoinformatics, bioinformatics, and chemogenomics studies. ( 0,56701423686141 )
J Chem Inf Model - In silico target predictions: defining a benchmarking data set and comparison of performance of the multiclass Na?ve Bayes and Parzen-Rosenblatt window. ( 0,565767338505532 )
J Chem Inf Model - Quantitative structure-activity relationship models of chemical transformations from matched pairs analyses. ( 0,56481550788982 )
J Chem Inf Model - Exploring uncharted territories: predicting activity cliffs in structure-activity landscapes. ( 0,56431914949637 )
J Chem Inf Model - Structure-based virtual screening approach for discovery of covalently bound ligands. ( 0,564114815536143 )
J Chem Inf Model - Hit expansion approaches using multiple similarity methods and virtualized query structures. ( 0,562746893446951 )
J Chem Inf Model - Prediction of individual compounds forming activity cliffs using emerging chemical patterns. ( 0,562583126078267 )
J Chem Inf Model - RS-predictor: a new tool for predicting sites of cytochrome P450-mediated metabolism applied to CYP 3A4. ( 0,56089181109809 )
J Chem Inf Model - FAst MEtabolizer (FAME): A rapid and accurate predictor of sites of metabolism in multiple species by endogenous enzymes. ( 0,560706162295258 )
J Chem Inf Model - MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs. ( 0,560346658159039 )
BMC Med Inform Decis Mak - Finding type 2 diabetes causal single nucleotide polymorphism combinations and functional modules from genome-wide association data. ( 0,559008744601929 )
J Chem Inf Model - Compound set enrichment: a novel approach to analysis of primary HTS data. ( 0,558705230388432 )
J Chem Inf Model - Extraction of discontinuous structure-activity relationships from compound data sets through particle swarm optimization. ( 0,55761015756551 )
J Chem Inf Model - ColBioS-FlavRC: a collection of bioselective flavonoids and related compounds filtered from high-throughput screening outcomes. ( 0,557475315366648 )
J Chem Inf Model - Harvesting classification trees for drug discovery. ( 0,557441111820638 )
J Chem Inf Model - Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries. ( 0,55738150478201 )
Comput Biol Chem - The optimization of running time for a maximum common substructure-based algorithm and its application in drug design. ( 0,556817452935677 )
J Chem Inf Model - Prediction of new bioactive molecules using a Bayesian belief network. ( 0,556446230699491 )
J Chem Inf Model - Ligand- and structure-based virtual screening for clathrodin-derived human voltage-gated sodium channel modulators. ( 0,556427061968552 )
J Chem Inf Model - Discovery of novel histamine H4 and serotonin transporter ligands using the topological feature tree descriptor. ( 0,555252764254933 )
J Chem Inf Model - Similarity boosted quantitative structure-activity relationship--a systematic study of enhancing structural descriptors by molecular similarity. ( 0,554288455673534 )
J Chem Inf Model - Virtual fragment screening: discovery of histamine H3 receptor ligands using ligand-based and protein-based molecular fingerprints. ( 0,554161754401919 )
J Chem Inf Model - Validation of the AmpC ?-lactamase binding site and identification of inhibitors with novel scaffolds. ( 0,553747591876184 )
J Chem Inf Model - Increasing the coverage of medicinal chemistry-relevant space in commercial fragments screening. ( 0,553492972504891 )
J Chem Inf Model - Comparative analysis of pharmacophore screening tools. ( 0,553356916368547 )
J Chem Inf Model - DiSCuS: an open platform for (not only) virtual screening results management. ( 0,552997876492231 )
J Chem Inf Model - Maximum-score diversity selection for early drug discovery. ( 0,55174789399876 )